Microbiological features of Pseudomonas aeruginosa in children with Cystic Fibrosis

O.V. Ishchenko; D.O.  Stepanskyi

doi:10.26641/2307-0404.2021.3.242130

Authors

O.V. Ishchenko Dnipro State Medical University, Vernadsky str., 9, Dnipro, 49044, Ukraine https://orcid.org/0000-0001-7677-5062
D.O. Stepanskyi Dnipro State Medical University, Vernadsky str., 9, Dnipro, 49044, Ukraine https://orcid.org/0000-0001-6350-8176

DOI:

https://doi.org/10.26641/2307-0404.2021.3.242130

Keywords:

cystic fibrosis, chronic infection, Pseudomonas aeruginosa, airway microbiome, resistance

Abstract

The purpose of the study was to determine the frequency rate of Pseudomonas aeruginosa infection among children with cystic fibrosis (CF) in Dnipro region and to provide microbiological characteristics of the obtained isolates. The study was conducting from January 2019 to December 2020. Children with genetically confirmed CF diagnosis were enrolled. The main research method was bacteriological with identification of microorganisms by biochemical properties; antimicrobial susceptibility was determined by disk-diffusion method. Biological material: mucus from a deep smear from the posterior pharyngeal wall, sputum and tracheobronchial lavage waters. The Leeds criteria were used to define persons with chronic infection. The study involved 21 children. We collected 183 respiratory samples with 49 isolates of P. aeruginosa. The most important co-existing pathogens were Staphylococcus aureus, Aspergillus spp. and Candida spp. In our study, P. aeruginosa was associated with Aspergillus spp. (χ²=20.952; df=1; p˂0.001). Mucoid isolates were found in 24.49% of cases. P. aeruginosa showed variable sensitivity to different groups of antimicrobial agents, but the highest resistance was to penicillins. Mucoid P. aeruginosa was more resistant to penicillins (p˂0.001) and cephalosporins (p=0.036). Infection P. aeruginosa is frequent among children with CF; there were three children with chronic bronchopulmonary infection P. aeruginosa in Dnipro region in the end of 2020. The likelihood of Aspergillus spp. infection was higher in the case of current P. aeruginosa infection. P. aeruginosa showed variable susceptibility to different groups of antimicrobial agents, but mucoid isolates were more resistant.

References

Ilchenko SI. [Clinical and microbiological features of cystic fibrosis in children of a large industrial city]. Pathologia. 2014;3:73-77. Ukrainian. Available from: http://nbuv.gov.ua/UJRN/pathology_2014_3_17.

Blanchard AC, Waters VJ. Microbiology of Cystic Fibrosis Airway Disease. Semin Respir Crit Care Med. 2019;6(40):727-36.

doi: https://doi.org/10.1055/s-0039-1698464

Alonso B, Fernández-Barat L, Di Domenico EG, Marín M, Cercenado E, Merino I, de Pablos M, Muñoz P, Guembe M. Characterization of the virulence of Pseudomonas aeruginosa strains causing ventilator-associated pneumonia. BMC Infect Dis. 2020;20(1):909. doi: https://doi.org/10.1186/s12879-020-05534-1

Clinical Guidelines: Care of Children with Cystic Fibrosis. Royal Brompton Hospital. S. Alexander et al. Endorsed by the Medicines Management Board of Royal Brompton & Harefield NHS Foundation Trust; 2014.

Keown K, Reid A, Moore JE, Taggart CC, Downey DG. Coinfection with Pseudomonas aeruginosa and Aspergillus fumigatus in cystic fibrosis. Eur Respir Rev. 2020;29(158):200011. doi: https://doi.org/10.1183/16000617.0011-2020

Bhagirath AY, Li Y, Somayajula D, Dadashi M, Badr S, Duan K. Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. BMC Pulm Med. 2016;16(1):174.

doi: https://doi.org/10.1186/s12890-016-0339-5

Workentine M, Poonja A, Waddell B, et al. Development and Validation of a PCR Assay To Detect the Prairie Epidemic Strain of Pseudomonas aeruginosa from Patients with Cystic Fibrosis. J Clin Microbiol. 2016 ;54(2) :489-91. doi: https://doi.org/10.1128/JCM.02603-15

Zolin A, Orenti A, Naehrlich L, Jung A, van Rens J, et al. ECFS Patients Registry: Annual Data Report (year 2018). European Cystic Fibrosis Society, Denmark; 2020. p. 173. Available from: https://www.ecfs.eu/projects/ecfs-patient-registry/annual-reports

Garcia-Clemente M, de la Rosa D, Máiz L, Gi¬rón R, Blanco M, Olveira C, Canton R, Martinez-García MA. Impact of Pseudomonas aeruginosa Infection on Patients with Chronic Inflammatory Airway Diseases. J Clin Med. 2020;9(12):3800. doi: https://doi.org/10.3390/jcm9123800

Mall MA, Hartl D. CFTR: cystic fibrosis and beyond. Eur Respir J. 2014;44(4):1042-54. doi: https://doi.org/10.1183/09031936.00228013

Orazi G, O’Toole GA. Pseudomonas aeruginosa Alters Staphylococcus aureus Sensitivity to Vancomycin in a Biofilm Model of Cystic Fibrosis Infection. mBio. 2017;4(8):e00873-17. doi: https://doi.org/10.1128/ mBio

Sarah J. Pitt. Clinical Microbiology for Diagnostic Laboratory Scientists. John Wiley & Sons Ltd; 2018. p. 275.

Spoonhower KA, Davis PB. Epidemiology of Cystic Fibrosis. Clin Chest Med. 2016;37(1):1-8. PMID: 26857763. doi: https://doi.org/10.1016/j.ccm.2015.10.002

The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0; 2020. URL: http://www.eucast.org.

Yadav SK, Singh S, Gupta R. Biomedical Statistics. A Beginner's Guide. 1st ed. Springer, Singapore; 2019. p. 342.

doi: https://doi.org/10.1007/978-981-32-9294-9